Philip Ball

Philip Ball currently serves as the Patient Value & Access Director at Napp Pharmaceuticals Limited, a position held since March 2022. Previously, Philip was the Regional Market Access Lead (Interim) at the same company and held various roles at AstraZeneca and Mundipharma, including Senior Indication Lead and Senior Health Economics and Outcomes Research Lead. Philip's background includes significant experience in medical information, market access, and health technology appraisals, with roles at companies such as Balloon Medical Ltd, Daiichi Sankyo, Astellas Pharma, and Roche Pharmaceuticals. Philip holds a BSc (Hons) in Biology (Molecular Genetics) from the University of Bristol and has a strong track record of leadership and expertise in medical writing, compliance, and strategic support within the pharmaceutical industry.